New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
04:55 EDTA, A, A, BRKR, BRKR, BRKR, XLS, XLS, XLS, FLIR, FLIR, FLIR, PH, PH, PH, PKI, PKI, PKI, TMO, TMO, TMOAmerican Society for Mass Spectrometry to hold a conference
62nd ASMS Conference on Mass Spectrometry to be held in Baltimore, Maryland on June 15-19.
News For A;BRKR;XLS;FLIR;PH;PKI;TMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 18, 2015
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
14:20 EDTFLIRFLIR Systems to host analyst and investor day
Subscribe for More Information
07:46 EDTXLSExelis achieves factory acceptance testing for Aireon's ADS-B system
Subscribe for More Information
07:22 EDTPKIUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
May 15, 2015
10:13 EDTPHHigh option volume stocks
High option volume stocks: POST SFM GSVC HGG HUN PH JWN CAR ONTY LBTYA
09:40 EDTPHEquity options with increasing volume
Subscribe for More Information
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 14, 2015
09:11 EDTBRKRBruker secures contract for DE-tector ETD system
Subscribe for More Information
May 13, 2015
12:39 EDTTMOOn The Fly: Top stock stories at midday
Subscribe for More Information
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
May 12, 2015
16:25 EDTTMOOn The Fly: Top stock stories for Tuesday
Stocks began the session deep in negative territory as bond yields in Europe and the U.S. were moving higher. The market saw its lows shortly after the open and soon began to recapture some of its losses. By noon, the losses were cut in half and the Dow made it all the way back to positive ground by the afternoon. Unable to gather any upside momentum, the rally stalled and the averages limped into the close. ECONOMIC EVENTS: In the U.S., the National Federation of Independent Business' small business optimism rose 1.7 points to 96.9 in April, versus expectations for a 96.0 reading. The JOLTs report showed job openings fell 150K to 4.99M in March, versus expectations for 5.11M openings. The 10-year U.S. Treasury yield climbed at high as 2.37% earlier in the session, which was its highest intraday mark since last November, before easing back by midday. Outside of the U.S., bond yields surged on 10-year notes in Japan, Italy, Spain, Portugal, and Germany. COMPANY NEWS: Shares of AOL (AOL) advanced $7.93, or 18.62%, to $50.52 after Verizon (VZ) agreed to buy the company for $50 per share in a deal valued at $4.4B. Verizon's John Stratton, speaking at the Jefferies 2015 Global TMT Conference, said the AOL deal was primarily about ad technology and Re/code reported that "one scenario" the service has heard about is that Verizon plans to spin off some or all of the content operations it is acquiring by buying AOL, such as the Huffington Post. Yahoo (YHOO) also rose 24c, or 0.55%, to $43.84, as Cantor Fitzgerald analyst Youssef Squali said he now views it as the "last remaining large scale digital media company of its kind." MAJOR MOVERS: Among the notable gainers was Pall Corp. (PLL), which advanced $19.31, or 19.44%, to $118.62 after The Wall Street Journal reported that the company is near a possible sale and listed Danaher (DHR) and Thermo Fisher (TMO) as potential buyers. Also higher was Pain Therapeutics (PTIE), which gained 68c, or 35.05%, to $2.62 after announcing that a study of its lead drug candidate, that is specifically designed to discourage certain common methods of drug tampering and misuse, demonstrated with statistical significance that both intact and chewed Remoxy were less "liked" than immediate-release oxycodone on the two primary endpoints of Drug Liking and Drug High. Among the noteworthy losers was ITT Educational Services (ESI), which plunged $1.75, or 43.53%, to $2.27 after the SEC announced that it had charged the company, along with its CEO and CFO, with fraud. Also lower were shares of NewLink Genetics (NLNK), which dropped $15.59, or 29.9%, to $36.55 after stating that it would continue its flagship IMPRESS trial as planned despite disclosing the FDA did not endorse management's plan to change the statistical analysis plan as defined in the original protocol. INDEXES: The Dow fell 36.94, or 0.2%, to 18,068.23, the Nasdaq slid 17.38, or 0.35%, to 4,976.19, and the S&P 500 dropped 6.21, or 0.29%, to 2,099.12.
14:04 EDTTMOPall Corp. a better strategic fit for Thermo Fisher than Danaher, says Mizuho
Subscribe for More Information
12:34 EDTTMOOn The Fly: Top stock stories at midday
Subscribe for More Information
10:45 EDTTMOAnalyst says Pall deal may spark more life sciences M&A
Subscribe for More Information
09:47 EDTTMOPall Corp. bids due later this week, CNBC's Faber reports
David Faber on CNBC reported that bids for Pall Corp. (PLL) from Danaher (DHR) and Thermo Fisher (TMO) are due later this week. The auction is being led by Goldman Sachs (GS), Faber adds. He notes Danaher is likely going to offer an all-cash bid whereas Thermo Fisher will use up to $2B of equity. Faber said an offer price of $120 per share for Pall is likely the top of the range. The Wall Street Journal reported last night some of these details.
08:52 EDTPKIPerkinElmer management to meet with Leerink
Subscribe for More Information
07:46 EDTTMODanaher has upper hand to acquire Pall, says Jefferies
After the Wall Street Journal reported that Pall Corp. (PLL) is near a possible sale and listed Danaher (DHR) and Thermo Fisher (TMO) as potential buyers, Jefferies says it believes Danaher has the upper hand in getting the deal done given its greater relative balance sheet capacity. The firm views both companies as logical buyers for Pall and notes a takeout bid of around $13B implies a share price of $120. The firm has a Buy rating on Pall.
07:31 EDTTMOThermo Fisher acquisition of Pall Corp. could create 'powerhouse,' says UBS
UBS noted Thermo Fisher (TMO) was mentioned in a media report as a possible suitor for Pall Corp. (PLL) and feels if the two combine it could create a bio-production "powerhouse." The firm sees a potential deal as accretive and creating unparalleled scale. UBS also said that, based on current valuation, the potential for a deal is barely being priced into Thermo Fisher shares. UBS reiterated its Buy rating and $160 price target on Thermo Fisher shares.
06:30 EDTTMOPall volatility flat, Danaher, Thermo Fisher to submit final bids, WSJ reports
Subscribe for More Information
May 11, 2015
19:22 EDTTMODanaher, Thermo Fisher to submit final bids for Pall, WSJ says
Danaher (DHR) and Thermo Fisher (TMO) are competing to acquire Pall (PLL), with final bids due later this week, reports The Wall Street Journal, citing people familiar with the matter. A deal could be valued at $13B or more, notes the Journal. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use